Author:
Darwish Ibrahim A,Alzoman Nourh Z,Abuhejail Reem M,El-Samani Tilal E
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. World Health Organization: 2005, Report, Geneva,
http://www.who.int/cancer/en
,
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M: Cancer statistics. Cancer J Clinicians. 2007, 57B: 43-66.
3. Lokhorst H: Clinical features and diagnostic criteria. Myeloma. Edited by: Singhal S, Mehta J. 2002, Martin Dunitz Ltd., London, 151-168.
4. Tariman JD, Estrella SM: The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing. Oncol Nursing Forum. 2005, 32: E127-E138. 10.1188/05.ONF.E127-E138.
5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Siegel D, Crowley J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999, 341: 1565-1571. 10.1056/NEJM199911183412102.